Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved
Recipient : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Naari Completes Acquisition of ANDAs from Intas Pharmaceuticals
Details : The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over t...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved
Recipient : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?